Cultivating New Frontiers of Science
Across its two-decade history, TCG has funded key advancements within biotechnology, nurturing science into successful ventures and therapeutic breakthroughs.
Platform and Opportunity Funds
TCG Platform funds are our legacy capital deployment model, used to partner with founders and entrepreneurs as they build companies with rich pipeline potential from early-stage drug discovery through exit.
TCG’s Platform funds selectively invest in a small cohort of highly vetted ideas and teams each with the potential for multiple shots on goal.
TCG’s Platform funds focus on 3-4 investments per year and average 10-12 portfolio companies per fund with $50-60+ million typically invested in each company.
TCG Opportunity funds build on the momentum of our Platform funds by providing a flexible pool of capital to support of our most promising companies through later stages of development and concentrate ownership within our portfolio.
TCG Labs Fund + Soleil R&D
TCG Labs-Soleil represents a pioneering venture-biotech model.
TCG Labs-Soleil integrates a dedicated venture fund of $400 million (TCG Labs) with an evergreen R&D hub led by top-tier scientists and drug developers (Soleil).
Launched in 2024, TCG Labs-Soleil is focused on single-asset programs for efficient discovery and development of biologic-based therapies.
TCG Labs-Soleil’s mission: to efficiently translate scientific insights into therapeutic solutions for patients burdened by serious diseases.
TCG Crossover Funds
TCG Crossover (TCGX) is the first crossover fund debuted under the TCG ecosystem, dedicated to investing in later-stage investments for both private and publicly-traded companies.
Launched in 2021, TCGX is focused on investing in innovative pre-IPO and public drug discovery companies.
TCGX’s goal is to support the translation of cutting-edge science into products that will make a meaningful difference for patients.
*TCGX is operationally independent of The Column Group (TCG)
An Ecosystem Strategy Fueled by an Edge-to-Edge Investment Model
TCG’s novel approach to venture capital funding harnesses an edge-to-edge investment model paired with an ecosystem strategy to realize true therapeutic breakthroughs.
Mission
Cultivating new frontiers of science into successful ventures and unprecedented therapeutic breakthroughs.
Our focus: Pursuing the Unprecedented
TCG sees the future of biotech through the lens of science and industry, backing ideas that represent creative, innovative leaps forward in medicine and business.
Our impact: Realizing True Therapeutic Breakthroughs
TCG swings for the fences in a think big, go bold kind of way – actively partnering with scientific founders to channel innovation and realize potential through value-driving platforms, assets and business models.
The TCG Credo
We see the future of biotech as a fearless pursuit of new frontiers in medicine and business.
We partner with visionary entrepreneurs, investors and team members to take creative, innovative leaps forward.
We are adept at knowing when, where and how to lean into opportunities with the potential to upend convention.
We pride ourselves on going deep — supporting scientific founders in their journey to actualize innovation through value-driving platforms, assets and business models.
We map the end game, working tirelessly to deliver for stakeholders across our ecosystem.
We unite in a shared mission: cultivating new frontiers of science into successful ventures and unprecedented therapeutic breakthroughs. Join us.
In The News
